186 related articles for article (PubMed ID: 26132521)
21. Spatial modeling of HIV cryptic viremia and 2-LTR formation during raltegravir intensification.
Cardozo EF; Luo R; Piovoso MJ; Zurakowski R
J Theor Biol; 2014 Mar; 345():61-9. PubMed ID: 24378646
[TBL] [Abstract][Full Text] [Related]
22. In vitro and in vivo transport and delivery of phosphorothioate oligonucleotides with cationic liposomes.
Miyano-Kurosaki N; Barnor JS; Takeuchi H; Owada T; Nakashima H; Yamamoto N; Matsuzaki T; Shimada F; Takaku H
Antivir Chem Chemother; 2004 Mar; 15(2):93-100. PubMed ID: 15185727
[TBL] [Abstract][Full Text] [Related]
23. Europium sulfide nanoprobes predict antiretroviral drug delivery into HIV-1 cell and tissue reservoirs.
Herskovitz J; Hasan M; Machhi J; Mukadam I; Ottemann BM; Hilaire JR; Woldstad C; McMillan J; Liu Y; Seravalli J; Sarella A; Gendelman HE; Kevadiya BD
Nanotheranostics; 2021; 5(4):417-430. PubMed ID: 33972918
[No Abstract] [Full Text] [Related]
24. Antiretroviral Hydrophobic Core Graft-Copolymer Nanoparticles: The Effectiveness against Mutant HIV-1 Strains and in Vivo Distribution after Topical Application.
Leporati A; Gupta S; Bolotin E; Castillo G; Alfaro J; Gottikh MB; Bogdanov AA
Pharm Res; 2019 Mar; 36(5):73. PubMed ID: 30919089
[TBL] [Abstract][Full Text] [Related]
25. Antiviral effects of mifepristone on human immunodeficiency virus type-1 (HIV-1): targeting Vpr and its cellular partner, the glucocorticoid receptor (GR).
Schafer EA; Venkatachari NJ; Ayyavoo V
Antiviral Res; 2006 Dec; 72(3):224-32. PubMed ID: 16889838
[TBL] [Abstract][Full Text] [Related]
26. Raltegravir Once-Daily Tablet: A Review in HIV-1 Infection.
Deeks ED
Drugs; 2017 Oct; 77(16):1789-1795. PubMed ID: 29071467
[TBL] [Abstract][Full Text] [Related]
27. In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.
Kobayashi M; Yoshinaga T; Seki T; Wakasa-Morimoto C; Brown KW; Ferris R; Foster SA; Hazen RJ; Miki S; Suyama-Kagitani A; Kawauchi-Miki S; Taishi T; Kawasuji T; Johns BA; Underwood MR; Garvey EP; Sato A; Fujiwara T
Antimicrob Agents Chemother; 2011 Feb; 55(2):813-21. PubMed ID: 21115794
[TBL] [Abstract][Full Text] [Related]
28. Ultrasmall gold nanosatellite-bearing transformable hybrid nanoparticles for deep tumor penetration.
Son S; Deepagan VG; Shin S; Ko H; Min J; Um W; Jeon J; Kwon S; Lee ES; Suh M; Lee DS; Park JH
Acta Biomater; 2018 Oct; 79():294-305. PubMed ID: 30134209
[TBL] [Abstract][Full Text] [Related]
29. Small molecule ONC201 inhibits HIV-1 replication in macrophages via FOXO3a and TRAIL.
Zhao R; Li Y; Gorantla S; Poluektova LY; Lin H; Gao F; Wang H; Zhao J; Zheng JC; Huang Y
Antiviral Res; 2019 Aug; 168():134-145. PubMed ID: 31158413
[TBL] [Abstract][Full Text] [Related]
30. Endosomal trafficking of nanoformulated antiretroviral therapy facilitates drug particle carriage and HIV clearance.
Guo D; Zhang G; Wysocki TA; Wysocki BJ; Gelbard HA; Liu XM; McMillan JM; Gendelman HE
J Virol; 2014 Sep; 88(17):9504-13. PubMed ID: 24920821
[TBL] [Abstract][Full Text] [Related]
31. Immunomodulatory activities of curcumin-stabilized silver nanoparticles: Efficacy as an antiretroviral therapeutic.
Sharma RK; Cwiklinski K; Aalinkeel R; Reynolds JL; Sykes DE; Quaye E; Oh J; Mahajan SD; Schwartz SA
Immunol Invest; 2017 Nov; 46(8):833-846. PubMed ID: 29058549
[TBL] [Abstract][Full Text] [Related]
32. Raltegravir blocks the infectivity of red-fluorescent-protein (mCherry)-labeled HIV-1
Ogata-Aoki H; Higashi-Kuwata N; Hattori SI; Hayashi H; Danish M; Aoki M; Shiotsu C; Hashiguchi Y; Hamada A; Kobayashi H; Ihn H; Okada S; Mitsuya H
Antiviral Res; 2018 Jan; 149():78-88. PubMed ID: 28893602
[TBL] [Abstract][Full Text] [Related]
33. Antiretroviral nanoparticles: an extended drug delivery modality.
Destache CJ; Goede M; Belgum T
Ther Deliv; 2010 Sep; 1(3):383-6. PubMed ID: 22816141
[TBL] [Abstract][Full Text] [Related]
34. Penetration of polymeric nanoparticles loaded with an HIV-1 inhibitor peptide derived from GB virus C in a vaginal mucosa model.
Ariza-Sáenz M; Espina M; Bolaños N; Calpena AC; Gomara MJ; Haro I; García ML
Eur J Pharm Biopharm; 2017 Nov; 120():98-106. PubMed ID: 28842284
[TBL] [Abstract][Full Text] [Related]
35. Doxorubicin loaded magnetic gold nanoparticles for in vivo targeted drug delivery.
Elbialy NS; Fathy MM; Khalil WM
Int J Pharm; 2015 Jul; 490(1-2):190-9. PubMed ID: 25997662
[TBL] [Abstract][Full Text] [Related]
36. Substitution of nevirapine or raltegravir for protease inhibitor vs. rosuvastatin treatment for the management of dyslipidaemia in HIV-infected patients on stable antiretroviral therapy (Nevrast study).
Calza L; Magistrelli E; Colangeli V; Borderi M; Bussini L; Bon I; Re MC; Viale P
Infect Dis (Lond); 2017 Oct; 49(10):737-747. PubMed ID: 28683645
[TBL] [Abstract][Full Text] [Related]
37. In vitro cytotoxicity and phototoxicity of surface-modified gold nanoparticles associated with neutral red as a potential drug delivery system in phototherapy.
Verissimo TV; Santos NT; Silva JR; Azevedo RB; Gomes AJ; Lunardi CN
Mater Sci Eng C Mater Biol Appl; 2016 Aug; 65():199-204. PubMed ID: 27157744
[TBL] [Abstract][Full Text] [Related]
38. [Potential of integrase inhibitors to deplete HIV reservoirs or prevent their replenishment].
Llibre JM; Martínez-Picado J
Enferm Infecc Microbiol Clin; 2008 Nov; 26 Suppl 12():17-22. PubMed ID: 19572421
[TBL] [Abstract][Full Text] [Related]
39. Molecular dynamics simulation study of gold nanosheet as drug delivery vehicles for anti-HIV-1 aptamers.
Ajamgard M; Sardroodi JJ; Ebrahimzadeh AR; Kamelabad MR
Comput Biol Chem; 2021 Dec; 95():107595. PubMed ID: 34739903
[TBL] [Abstract][Full Text] [Related]
40. Polymeric nanoparticles for enhancing antiretroviral drug therapy.
Govender T; Ojewole E; Naidoo P; Mackraj I
Drug Deliv; 2008 Nov; 15(8):493-501. PubMed ID: 18720133
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
